Table 3 Comparison of discrimination (c-statistic) between development study and validation, 5-year follow-up
Outcomes (5 -year) | |||
|---|---|---|---|
Death | Cancer Diagnosis | Rate | |
a: Validation (UKB) | |||
General CMS | 0.654 (0.648–0.660) | 0.552 (0.548–0.555) | 0.667 (0.666–0.668) |
Mortality CMS | 0.685 (0.679–0.690) | 0.643 (0.64–0.646) | 0.625 (0.624–0.625) |
Hospital CMS | 0.699 (0.693–0.704) | 0.643 (0.639–0.646) | 0.643 (0.642–0.644) |
Unweighted Count Score | 0.644 (0.638–0.0.650) | 0.553 (0.549–0.556) | 0.668 (0.668–0.669) |
b: Development (CPRD), from Payne et al. (2020) | |||
General CMS | 0.824 (0.819–0.830) | - | 0.667 (0.665–0.668) |
Mortality CMS | 0.890 (0.886–0.894) | - | - |
Hospital CMS | - | - | - |
Unweighted Count Score | - | - | - |